Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01846741 · ClinicalTrials.gov registry record · NA

VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)

A NA study of Epilepsy, sponsored by Cyberonics.

Completed
Registry status
NA
Development phase
20
Enrollment target
15
Study locations

NCT01846741: Completed NA study of Epilepsy, sponsored by Cyberonics.

NCT01846741 is a NA study of Epilepsy that has completed, run by Cyberonics. The registered enrollment target is 20 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01846741, a NA study of Epilepsy, has completed, sponsored by Cyberonics.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
15
Study locations

Study Summary

Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator

Primary Outcome

The purpose for determining the effect size was to power a stage 2 study. At the conclusion of stage 1 of the E-37 study, it was determined that another study would not be necessary as it would not provide incremental clinical benefit information above what has already been collected. Therefore, computation of effect size was not necessary.

Conditions Studied

Interventions

  • DEVICE M106 VNS Therapy System

Study Locations (15)

Texas

  • - Dallas
  • - Houston

Arizona

  • - Phoenix

California

  • - Stanford

Florida

  • - Tampa

Georgia

  • - Atlanta

Illinois

  • - Chicago

Michigan

  • - Ann Arbor

Minnesota

  • - Saint Paul

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-07
Est. Completion 2015-08
Phase NA
Cyberonics

15 total trials

What the finished NCT01846741 record still lists

NCT01846741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which M106 VNS Therapy System is the first listed.

NCT01846741 lists 15 locations in 14 states (Texas, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT01846741 about?

NCT01846741 is a clinical study titled "VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)". Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator

What is the current status of trial NCT01846741?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-07. Estimated completion is 2015-08.

What conditions does trial NCT01846741 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT01846741?

The interventions under investigation include: M106 VNS Therapy System (DEVICE).

Who is sponsoring clinical trial NCT01846741?

This trial is sponsored by Cyberonics, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01846741 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01846741's enrollment target sits among peer trials

20 131st of 160 higher than 24 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01846741, the US trial registry maintained by the National Library of Medicine. NCT01846741 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.